Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia.
作者信息
Vuorio Alpo, Kovanen Petri T
机构信息
Mehiläinen Airport Health Centre, Vantaa, Finland; University of Helsinki, Department of Forensic Medicine, Helsinki, Finland.
Wihuri Research Institute, Helsinki, Finland.
出版信息
J Clin Lipidol. 2020 Sep-Oct;14(5):617-618. doi: 10.1016/j.jacl.2020.06.006. Epub 2020 Jun 15.
Abstract
摘要
相似文献
1
Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia.预防家族性高胆固醇血症的新冠肺炎患者出现内皮功能障碍和血栓形成事件。
J Clin Lipidol. 2020 Sep-Oct;14(5):617-618. doi: 10.1016/j.jacl.2020.06.006. Epub 2020 Jun 15.
2
Potential role of statins in COVID-19.他汀类药物在 COVID-19 中的潜在作用。
Int J Infect Dis. 2020 Jul;96:615-617. doi: 10.1016/j.ijid.2020.05.115. Epub 2020 Jun 2.
3
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.新冠肺炎（COVID-19）中的血栓形成——从维柯氏三联征的角度来看。
Clin Rheumatol. 2020 Sep;39(9):2529-2543. doi: 10.1007/s10067-020-05275-1. Epub 2020 Jul 11.
4
ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.COVID-19中的ACEI/ARB治疗：ACE2与SARS-CoV-2病毒对接的双刃剑
Crit Care. 2020 Jul 31;24(1):475. doi: 10.1186/s13054-020-03195-9.
5
Can beta-adrenergic blockers be used in the treatment of COVID-19?β-肾上腺素能阻滞剂可用于治疗新型冠状病毒肺炎吗？
Med Hypotheses. 2020 Sep;142:109809. doi: 10.1016/j.mehy.2020.109809. Epub 2020 May 5.
6
The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.高血压、血管紧张素转换酶2（ACE-2）与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）之间的相互作用：新出现的数据成为2019冠状病毒病（COVID-19）“迷宫”中的“阿里阿德涅之线” 。
Hellenic J Cardiol. 2020 Jan-Feb;61(1):31-33. doi: 10.1016/j.hjc.2020.05.003. Epub 2020 May 22.
7
COVID-19 and the pulmonary vascular injury.新型冠状病毒肺炎与肺血管损伤
J Renin Angiotensin Aldosterone Syst. 2020 Oct-Dec;21(4):1470320320972276. doi: 10.1177/1470320320972276.
8
Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach.新型冠状病毒感染中血管紧张素II的抑制作用：一种治疗方法。
Nefrologia (Engl Ed). 2020 May-Jun;40(3):213-216. doi: 10.1016/j.nefro.2020.04.006. Epub 2020 Apr 30.
9
COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.心力衰竭背景下COVID-19对肾素-血管紧张素系统的干扰
mBio. 2020 May 22;11(3):e00946-20. doi: 10.1128/mBio.00946-20.
10
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.肾素-血管紧张素系统抑制在 COVID-19 大流行期间的争议。
Nat Rev Nephrol. 2020 Jun;16(6):305-307. doi: 10.1038/s41581-020-0279-4.
引用本文的文献
1
Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection.家族性高胆固醇血症合并新型冠状病毒肺炎患者——感染期间及感染后均急需有效的降胆固醇治疗
Rev Cardiovasc Med. 2022 Dec 19;23(12):410. doi: 10.31083/j.rcm2312410. eCollection 2022 Dec.
2
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.靶向前蛋白转化酶枯草溶菌素 9（PCSK9）：从实验室到临床。
Signal Transduct Target Ther. 2024 Jan 8;9(1):13. doi: 10.1038/s41392-023-01690-3.
3
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022.2007 年至 2022 年 PCSK9 抑制剂的文献计量分析。
Front Endocrinol (Lausanne). 2023 Nov 29;14:1218968. doi: 10.3389/fendo.2023.1218968. eCollection 2023.
4
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.胆固醇稳态在健康和疾病中的调节：从机制到靶向治疗。
Signal Transduct Target Ther. 2022 Aug 2;7(1):265. doi: 10.1038/s41392-022-01125-5.
5
The Multifaceted Biology of PCSK9.载脂蛋白 C-III（APOC3）基因的多态性与甘油三酯水平升高和心血管疾病（CVD）风险增加有关。
Endocr Rev. 2022 May 12;43(3):558-582. doi: 10.1210/endrev/bnab035.
6
Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism.高胆固醇血症与2019冠状病毒病：他汀类药物用于降低静脉血栓栓塞风险
Front Cardiovasc Med. 2021 Oct 13;8:711923. doi: 10.3389/fcvm.2021.711923. eCollection 2021.
7
Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition.家族性高胆固醇血症与2019冠状病毒病：一种危险但可治疗的血管病变状况。
Atheroscler Plus. 2021 Sep;43:3-6. doi: 10.1016/j.athplu.2021.08.001. Epub 2021 Aug 8.
8
Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction.家族性高胆固醇血症合并新冠病毒病患者：持续有效地降低胆固醇对于预防急性心肌梗死至关重要。
Am J Prev Cardiol. 2021 Sep;7:100224. doi: 10.1016/j.ajpc.2021.100224. Epub 2021 Jul 20.
9
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19.为何持续脂蛋白分离术对患有COVID-19的纯合子家族性高胆固醇血症患者至关重要。
J Clin Lipidol. 2021 Mar-Apr;15(2):379-380. doi: 10.1016/j.jacl.2021.02.002.
10
Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
Drugs. 2021 Jun;81(9):1125-1127. doi: 10.1007/s40265-021-01537-7. Epub 2021 May 28.
本文引用的文献
1
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
2
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
3
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.心血管考虑因素在 COVID-19 大流行期间的患者、医护人员和卫生系统。
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031. Epub 2020 Mar 19.
4
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.家族性高胆固醇血症和脂蛋白(a)升高：双重遗传性风险和新的治疗机会。
J Intern Med. 2020 Jan;287(1):2-18. doi: 10.1111/joim.12981.
5
Clinical effects of antiplatelet drugs and statins on D-dimer levels.抗血小板药物和他汀类药物对 D-二聚体水平的临床影响。
Eur J Clin Invest. 2018 Jul;48(7):e12944. doi: 10.1111/eci.12944. Epub 2018 May 13.
6
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.ODYSSEY FH I和FH II：735例杂合子家族性高胆固醇血症患者接受阿利西尤单抗治疗78周的结果
Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1.
7
Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography.通过冠状动脉计算机断层扫描血管造影术评估家族性高胆固醇血症患者的冠状动脉粥样硬化。
Am J Cardiol. 2015 Mar 15;115(6):724-9. doi: 10.1016/j.amjcard.2014.12.034. Epub 2015 Jan 6.
8
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.依洛尤单抗（AMG 145）抑制载脂蛋白 B 代谢通路治疗杂合子家族性高胆固醇血症（RUTHERFORD-2）：一项随机、双盲、安慰剂对照试验。
Lancet. 2015 Jan 24;385(9965):331-40. doi: 10.1016/S0140-6736(14)61399-4. Epub 2014 Oct 1.
9
Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia.炎症和血栓形成过程与家族性高胆固醇血症患儿的血管功能障碍有关。
Atherosclerosis. 2009 Jun;204(2):532-7. doi: 10.1016/j.atherosclerosis.2008.09.025. Epub 2008 Oct 5.
10
Statins and blood coagulation.他汀类药物与血液凝固
Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):287-94. doi: 10.1161/01.ATV.0000151647.14923.ec. Epub 2004 Nov 29.
Zotero 插件